Nanovery

Home      Nanorobots      Blog      About

Nanovery is developing nanorobots to diagnose the world’s deadliest diseases.

£ 133 bn

the global market size

of companion diagnostics

for cancer alone

70

%

the predicted increase

in incidence of cancer over the next 20 years

the number of deaths caused by cancer in 2018 according to World Health Organization

9 600 000

We are collaborating with renowned academic and clinical partners, giving us access

to thousands of patient samples and a proprietary dataset.

Recent advances have enabled early detection of cancers with just a blood sample, but this can still take 2 weeks. Cancer diagnoses using scans and tissue biopsy are slow, expensive and risky for patients. With the advancement of liquid biopsy, patients can be screened or diagnosed with just a blood sample, but this technique is still slow and expensive as it relies on PCR and sequencing.

Detecting cancer from a blood sample is still too slow

We are creating a point-of-care solution that is 10× cheaper and 100× faster

Our nanorobots are added to blood samples. When they capture a cancer biomarker they light up, allowing point-of-care testing. As there is no need for high capital expenditure, our nanorobots are 10 times cheaper. The whole process is also more than 100 times faster – a matter of one or two hours rather than weeks – as there is no need for complex lab protocols which require bioinformaticians to analyse the data.

Traditional research

Nanorobot

DNA computing and nanotech

NGS / qPCR

$5,000 / test

$500 / test

1 -2 hours

The ability to detect new cancer mutations thanks to Nanovery AI

Method

Price

Time

Opportunities

1-2 weeks

-

DNA from cancer cells is circulating in the bloodstream.

How does nanorobot work?

Nanorobots are introduced into the blood sample.

Each nanorobot looks for a specific cancer DNA mutation, similar to a "search function”.

After 1-2 hours nanorobot lights up if it found the right target.

Using AI, Nanovery is able to design new nanorobots capable of targeting new cancer mutations.

1

2

3

4

5

Contact us

Dr Jerzy Kozyra

Founder of Nanovery

jurek@nanovery.co.uk

Nanovery